Heparin sensitive and resistant vascular smooth muscle cells: Biology and role in restenosis

Connective Tissue Research

Volumn 37, Issue 1-2, 1998, Pages 87-103

  San Antonio, James D ^a   Verrecchio, Angela ^a   Pukac, Laurel A ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cell proliferation; Heparin; Heparin resistance; Restenosis; Vascular smooth muscle cells

Indexed keywords

EID: 0031970157     PISSN: 03008207     EISSN: None     Source Type: Journal    
DOI: 10.3109/03008209809028903     Document Type: Short Survey

References (96)

1. Casu, B. (1989). Structure of heparin and heparin fragments. Ann. N.Y. Acad. Sci., 556, 1-17.
2. Hascall, V. C., Heinegard, D. K. and Wight, T. N. (1991). Proteoglycans: metabolism and pathology. In Cell Biology of Extracellular Matrix, E. B. Hay, (ed.) (Plenum Press, New York) pp. 149-172.
3. Lindahl, U. and Hook, M. (1978). Glycosaminoglycans and their binding to biological macromolecules. Ann. Rev. Biochem., 47, 385-417.
4. Lindahl, U., Kusche, M., Lidholt, K. and Oscarsson, L. G. (1989). Biosynthesis of heparin and heparan sulfate. Ann. N.Y. Acad. Sci., 556, 36-50.
5. Maccarana, M., Casu, B. and Lindahl, U. (1993). Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J. Biol. Chem., 268, 23898-23905.
6. Walker, A., Turnbull, J. E. and Gallagher, J. T. (1994). Specific heparan sulfate saccharides mediate the activity of basic fibroblast growth factor. J. Biol. Chem., 269, 931-935.
7. Parthasarathy, N., Goldberg, I. J., Sivaram, P., Mulloy, B., Flory, D. M. and Wagner, W D. (1994). Oligosaccharide sequences of endothelial cell surface heparan sulfate proteoglycan with affinity for lipoprotein lipase. J. Biol. Chem., 269, 22391-22396.
8. David, G. (1993). Integral membrane heparan sulfate proteoglycans. FASEB J., 7, 1023-1030.
9. Jackson, R. L., Busch, S. J. and Cardin, A. D. (1991). Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol. Rev., 71, 481-539.
10. Karnovsky, M. J., Wright, T. C., Jr., Castellot, J. J., Jr., Chaoy, J., Lormeau, J. C. and Petitou, M. (1989). Heparin, heparan sulfate, smooth muscle cells, and atherosclerosis. In Heparin and Related Polysaccharides Structure and Activities, vol. 556, B. Bolland, (ed.) (N.Y. Acad. Sci., New York) pp. 268-281.
11. Lippman, M. M. (1968). Glycosaminoglycans and cell division. In Epithelial Mensenchymal Interactions. R. Fleischmajer, and R. E. Billngham, (eds.) (Williams & Wilkins. Baltimore) pp. 208-229.
12. Ross, R. and Glomset, J. A. (1976). The pathogenesis of atherosclerosis: Parts I and II. New. Engl. J. Med., 295, 369-377; 420-425.
13. Clowes, A. W. and Karnovsky, M. J. (1977). Suppression by heparin of smooth muscle proliferation in injured arteries. Nature, 265, 625-626.
14. Guyton, J. R., Rosenberg, R. D., Clowes, A. W. and Karnovsky, M. J. (1980). Inhibition of rat arterial smooth muscle cell proliferation by heparin. Circ. Res., 46, 625-634.
15. Castellot, J. J., Jr., Addonizio, M., Rosenberg, R. and Karnovsky, M. J. (1981). Cultured endothelial cells produce a heparin-like inhibitor of smooth muscle cell growth. J. Cell Biol., 90, 372-379.
16. Castellot, J. J., Jr., Beeler, D. L., Rosenberg, R. D. and Karnovsky, M. J. (1984). Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. J. Cell. Physiol., 120, 315-320.
17. Wright, T. C., Castellot, J. J., Jr., Petitou, M., Lormeau, J. C., Choay, J. and Karnovsky, M. J. (1989). Structural determinants of heparin's growth inhibitory activity. J. Biol. Chem., 264, 1534-1542.
18. Schmidt, A., Yoshida, K. and Buddeck, E. (1992). The antiproliferative activity of arterial heparan sulfate enriched with 2-O-Sulfated uronic acid residues. J. Biol. Chem., 267, 19242-19247.
19. Fritze, L. M., Reilly, C. F. and Rosenberg, R. D. (1985). An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. J. Cell Biol., 100, 1041-1049.
20. Edwards, I. J. and Wagner, W. D. (1992). Cell surface heparan sulfate proteoglycan and chondroitin sulfate proteoglycan of arterial smooth muscle cells. Am. J. Path., 140, 193-205.
21. Lawler, J. and Slayter, H. (1981). The release of heparin binding peptides from platelet thrombospondin by proteolytic action of thrombin, plasmin, and trypsin. Thromb. Res., 22, 267-279.
22. Sakashita, S., Engvall, E. and Ruoslahti, E. (1980). Basement membrane glycoprotein laminin binds to heparin. FEBS Letters, 116, 243-246.
23. Keller, K. M., Keller, J. M. and Kuhn, K. (1986). The C-terminus of type I collagen is a major binding site for heparin. Biochem. Biophys. Acta., 882, 1-5.
24. San Antonio, J. D., Lander, A. D., Karnovsky, M. J. and Slayter, H. S. (1994). Mapping the heparin-binding sites on type I collagen monomers and fibrils. J. Cell Biol., 125, 1179-1188.
25. San Antonio, J. D., Karnovsky, M. J., Gay, S., Sanderson, R. D. and Lander, A. D. (1994). Interactions of syndecan-1 and heparin with human collagens. Gycobiol., 4, 327-332.
26. Lark, M. W. and Culp, L. A. (1984). Multiple classes of heparan sulfate proteoglycans from fibroblast substratum adhesion sites, affinity fractionation on columns of platelet factor 4, plasma fibronectin and octyl-sepharose. J. Biol. Chem., 259, 6773-6782.
27. Woods, A., Couchman, J. R., Johansson, S. and Hook, M. (1986). Adhesion and cytoskeletal organization of fibroblasts in response to fibronectin fragments. EMBO J., 5, 665-670.
28. Gill, P. J., Silbert, C. K. and Silbert, J. E. (1986). Effects of heparan sulfate removal on attachment of fibroblasts and endothelial cells. Biochem., 25, 405-410.
29. Brennan, M. J., Oldberg, A., Hayman, E.G. and Ruoslathi, E. (1983). Effect of a proteoglycan produced by rat tumor cells on their adhesion to fibronectin-collagen substrata. Cancer Res., 43, 4302-4307.
30. San Antonio, J. D., Lander, A. D., Wright, T. C. and Karnovsky, M. J. (1992). Heparin inhibits the attachment and growth of Balb c/3T3 fibroblasts on collagen substrata. J. Cell. Physiol., 150, 8-16.
31. Piepkorn, M. W. and Chapman, D. L. (1985). Glycosaminoglycans and the substrate attachment of murine myeloma, 3T3, and cutaneous fibrosarcoma cells. Lab. Invest., 53, 22-29.
32. O'Neill, C., Jordan, P. and Ireland, G. (1986). Evidence for two distinct mechanisms of anchorage stimulation in freshly explanted and 3T3 Swiss mouse fibroblasts. Cell. 44, 489-496.
33. Campisi, J. and Medrana, E. E. (1983). Cell cycle perturbations in normal and transformed fibroblasts caused by detachment from the substratum. J. Cell. Physiol., 114, 53-60.
34. Liau, G. and Chan, L. M. (1989). Regulation of extracellular matrix RNA levels in cultured smooth muscle cells. J. Biol. Chem., 264, 10315-10320.
35. Brown, C. C. and Balian, G. (1987). Effect of heparin on synthesis of short chain collagen by chondrocytes and smooth muscle cells. J. Cell Biol. 105, 1007-1012.
36. Majack, R. A. and Bornstein, P. (1985). Heparin regulates the collagen phenotype of vascular smooth muscle cells: induced synthesis of an Mr 60,000 collagen. J. Cell Biol., 100, 613-619.
37. El Nabout, R., Martin, M., Remy, J., Robert, L. and LaFuma, C. (1989). Heparin fragments modulate the collagen phenotype of fibroblasts from radiation induced subcutaneous fibrosis. Exp. Molec. Path., 51, 111-122.
38. Gavriel, P. and Kagan, H.M. (1988). Inhibition by heparin of the oxidation of lysine in collagen by lysyl oxidase. Biochem., 27, 2811-2815.
39. Majack,0 R. A., Coates-Cook, S. and Bornstein, P. (1985). Platelet-derived growth factor and heparin-like glycosaminoglycans regulate thrombospondin synthesis and deposition in the matrix by smooth muscle cells. J. Cell Biol., 101, 1059-1070.
40. Majack, R. A., Goodman, L. V. and Dixit, V. M. (1988). Cell surface thrombospondin is functionally essential for vascular smooth muscle cell proliferation. J. Cell Biol., 106, 415-422.
41. Wight, T. (1985). Proteoglycans in pathological conditions: atherosclerosis. Fed. Proc., 44, 381-385.
42. Wight, T. (1995). Cell biology of arterial proteoglycans. Arterioscl., 9, 1-20.
43. Snow, A. D., Bolender, R. P., Wight, T. N. and Clowes, A. W. (1990). Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells. Am. J. Path., 137, 313-330.
44. Potter-Pergio, S. and Wight, T. (1996). Heparin causes the accumulation of heparan sulfate in cultures of arterial smooth muscle cells. Arch. Biochem. Biophys., 336, 19-26.
45. Castellot, J. J., Jr., Wong, K., Herman, R. L., Hoover, D. F., Albertini, T. C. and Wright, T. C. (1985). Binding and internalization of heparin by vascular smooth muscle cells. J. Cell. Physiol., 124, 13-20.
46. Stavenow, L., Lindblad, B. and Xu, C. B. (1995). Unfractionated heparin and low molecular weight heparin do not inhibit the growth of proliferating human arterial smooth muscle cells in culture. Eur. J. Vasc. Endovasc. Surg., 10 (2), 215-219.
47. Castellot, J. J., Jr., Pukac, L. A., Caleb, B. L., Wright, T. C. and Karnovsky, M. J. (1989). Heparin selectively inhibits a protein kinase C dependent mechanism of cell cycle progression in calf aortic smooth muscle cells. J. Cell Biol., 109, 3147-3156.
48. Dahlberg, C., Thompson, B., Joseph, P., Garg, H., Spence, C., Quinn, D., Boventre, J. and Hales, C. (1996). Differential effect of three commercial heparins on Na+/H+ exchange and growth of PASMC. Am. J. Physiol., 270, L260-L265.
49. Pukac, L., Carter, J., Ottlinger, M. E. and Karnovsky, M. J. (1997). Mechanisms of inhibition by heparin of PDGF stimulated MAP kinase activation in vascular smooth muscle cells. J. Cell. Physiol., 172, 69-78.
50. Ottlinger, M. E., Pukac, L. A. and Karnovsky, M. J. (1993). Heparin inhibits mitogen-activated protein kinase activation in intact rat vascular smooth muscle cells. J. Biol. Chem., 268, 19173-19176.
51. Pukac, L. A., Ottlinger, M. E. and Karnovsky, M. J. (1992). Heparin suppresses specific second messenger pathways for protooncogene expression in rat vascular smooth muscle cells. J. Biol. Chem., 267, 3707-3711.
52. Wachi, H., Seyama, Y. and Tajima, S. (1995). Modulation of elastin expression by heparin is dependent on the growth condition of vascular smooth muscle cells: Up-regulation of elastin expression by heparin in the proliferating cells is mediated by the inhibition of protein kinase C activity. J. Biochem., 118 (3), 582-586.
53. Herbert, J. M., Clowes, M.. Lea. H. J., Pascal, M. and Clowes, A. W. (1996). Protein kinase C alpha expression is required for heparin inhibition of rat smooth muscle cell proliferation in vitro and in vivo. J. Biol. Chem., 271, 25928-25935.
54. Pukac, L. A., Castellot, J. J., Wright, T. C., Caleb, B. L. and Karnovsky, M. J. (1990). Heparin inhibits c-fos and c-myc mRNA expression in vascular smooth muscle cells. Cell Reg., 1, 435-443.
55. Miralem, T., Wang, A., Whiteside, C. I. and Templeton, D. M. (1996). Heparin inhibits mitogen-activated protein kinase-dependent and -independent c-fos induction in mesangial cells. J. Biol. Chem., 271 (29), 17100-17106.
56. I phase of the cell cycle. J. Biol. Chem., 264, 6990-6995.
57. Clowes, A. W. (1992). Regulation of smooth muscle cell function by heparin. J. Vasc. Surg., 15, 911-913.
58. Fedarko, N. S. and Conrad. H. E. (1986). A unique heparan sulfate in the nuclei of hepatocytes: structural changes with the growth state of the cells. J. Cell Biol., 102, 587-599.
59. Busch, S. J., Martin, G. A., Barnhart, R. L., Mano, M., Cardin, A. D. and Jackson, R. L. (1992). Trans-repressor activity of nuclear glycosaminoglycans of fos and jun/AP-1 oncoprotein-mediated transcription. J. Cell Biol., 116, 31-42.
60. Castellot, J. J., Jr., Cochran, D. and Karnovsky, M. J. (1985). Effect of heparin on vascular smooth muscle cells I. Cell metabolism. J. Cell. Physiol., 124, 21-28.
61. Flint, N., Cove, F. L. and Evans, G. S. (1994). Heparin simulates the proliferation of intestinal epithelial cells in primary culture. J. Cell Sci., 107, 401-411.
62. Groggel, G. C., Marinides, G. N., Hovingh, P., Hamond, E. and Linker, A. (1990). Inhibition of rat mesangial cell growth by heparan sulfate. Am. J. Physiol., F259-F265.
63. Kimura, I., Nagaura, T., Naitoh, T., Kobayashi, S. and Kimura, M. (1992). Heparin inhibits the progression phase of subcultured endothelial cell proliferation in rat aorta. Jpn. J. Pharm., 60 (4), 369-375.
64. Resink, T. J., Scott-Burden, T., Baur, U., Burgin, M. and Buhler, F. R. (1989). Decreased susceptibility of cultured smooth muscle cells from SHR rats to growth inhibition by heparin. J. Cell. Physiol., 138, 137-144.
65. Eccleston-Joyner, C. A. and Gray, S. D. (1988). Arterial hypertrophy in the fetal and neonatal spontaneously hypertensive rat. Hypertension, 12, 513-518.
66. San Antonio, J. D., Karnovsky, M. J., Ottlinger, M. E., Schillig, R. and Pukac, L. A. (1993). Isolation of heparin-insensitive aortic smooth muscle cells. Arterioscl. Thromb., 13, 748-757.
67. Barzu, T., Herbert, J. M., Desmouliere, A., Carayon, P. and Pascal. M. (1994). Characterization of rat aortic smooth muscle cells resistant to the antiproliferative activity of heparin following long-term heparin treatment. J. Cell. Physiol., 160, 239-248.
68. Conroy, S., Hart, C., Perez-Reyes, N., Giachelli, C., Schwartz, S. and McDougall, J. (1995). Characterization of human aortic smooth muscle cells expressing HPV16 E6 and E7 open reading frames. Am. J. Path., 147, 753-762.
69. Reilly, C. (1990). Rat vascular smooth muscle cells immortalized with SV40 large T antigen possess defined smooth muscle cell characteristics including growth inhibition by heparin. J. Cell. Physiol., 142, 342-351.
70. Bennett, M. R., Evan, G. I. and Newby, A. C. (1994). Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of vascular smooth muscle cells by serum reduction, interferon-g, heparin, and cyclic nucleotide analogues and induces apoptosis. Circ. Res., 74, 525-536.
71. Caleb, B. L., Hardenbrook, M., Cherington, V. and Castellot, J. J., Jr. (1996). Isolation of vascular smooth muscle cell cultures with altered responsiveness to the antiproliferative effect of heparin. J. Cell. Physiol., 167, 185-195.
72. Bennett, M. R., Littlewood, T., Hancock, D., Evan, G. I. and Newby, A. C. (1994). Down-regulation of the c-myc protooncogene in inhibition of vascular smooth muscle cell proliferation: A signal for growth arrest? Biochem. J., 302, 710-708.
73. Fager, G., Hansson, G. K., Ottosson, P., Dahllof, B. and Bondjers, G. (1988). Human arterial smooth muscle cells in culture. Effects of platelet-derived growth factor and heparin on growth in vitro. Exp. Cell Res., 176, 319-335.
74. Caplice, N.M., West, M. J., Campbell, G. R. and Campbell, J. (1994). Inhibition of human vascular smooth muscle cell growth by heparin. The Lancet, 344, 97-98.
75. 3H]thymidine incorporation. J. Cardiovasc. Pharm., 25, 782-788.
76. Chan, P., Patel, M., Betteridge, L., Munro, E., Schachter, M., Wolfe, J. and Sever, P. (1993). Abnormal growth regulation of vascular smooth muscle cells by heparin in patients with restenosis. The Lancet, 341, 341-342.
77. Chan, P. (1994). Cell biology of human vascular smooth muscle. Ann. R. Coll. Surg. Engl., 76, 298-303.
78. Refson, J. S., Schachter, M., Patel, M. K., Chan, P., Wolfe, J. H. N. and Sever, P. (1995). Correlation of heparin binding with responsiveness in human vascular smooth muscle cells. Biochem. Soc. Trans., 23, 172S.
79. Barzu, T., Pascal, M., Maman, M., Roque, C., LaFont, F. and Rousselet, A. (1996). Entry and distribution of fluorescent antiproliferative heparin derivatives into rat vascular smooth muscle cells: Comparison between heparin-sensitive and heparin-resistant cultures. J. Cell. Physiol., 167, 8-21.
80. Letourneur, D., Caleb, B. L. and Castellot, J. J., Jr. (1995). Heparin binding, internalization, and metabolism in vascular smooth muscle cells: I. Upregulation of heparin binding correlates with antiproliferative activity. J. Cell. Physiol., 165, 676-686.
81. Letourneur, D., Caleb, B. L. and Castellot, J. J., Jr. (1995). Heparin binding, internalization, and metabolism in vascular smooth muscle cells: II. Degradation and secretion in sensitive and resistant cells. J. Cell. Physiol., 165, 687-695.
82. Sartore, S., Scatena, M., Chiavegato, A., Faggin, E., Giuriato, L. and Pauletto, P. (1994). Myosin isoform expression in smooth muscle cells during physiological and pathological vascular remodeling. J. Vasc. Res., 31, 61-81.
83. Dartsch, P. C., Voisard, R., Bauriedel, G., Hofling, B. and Betz, E. (1990). Growth characteristics and cytoskeletal organization of cultured smooth muscle cells from human primary, stenosing and restenosing lesions. Arterioscl. 10, 62-75.
84. Schwartz, S. M., Foy, L., Bowen-Pope, D. F. and Ross, R. (1990). Derivation and properties of platelet-derived growth factor-independent rat smooth muscle cells. Am. J. Path., 136, 1417-1428.
85. Blaes, N., Bourdillon, M. C., Lamaziere, J. M. D., Michaille, J. J., Anduiar, M. and Covacho, C. (1991). Isolation of two morphologically distinct cell lines from rat arterial smooth muscle expressing high tumorigenic potentials. In Vitro Cell Dev. Biol., 27A, 725-734.
86. Bondjers, G., Glukhova, M., Hansson, G. K., Postnov, Y. V., Reidy, M. A. and Schwanz, S. M. (1991). Hypertension and atherosclerosis. Cause and effect, or two effects with one unknown cause? Circ., 84, VI-2-VI-16.
87. Desmouliere, A., Rubbia-Brandt, L., Grau, G. and Gabbiani, G. (1992). Heparin induces alpha-smooth muscle actin expression in cultured fibroblasts and in granulation tissue myofibroblasts. Lab. Invest., 67 (6), 716-726.
88. Gibbons, G. H. and Dzau, V. J. (1996). Molecular therapies for vascular diseases. Science, 272, 689-693.
89. Davies, M. G. and Hagen, P. O. (1994). Pathobiology of intimal hyperplasia. Brit. J Surg., 81, 1254-1269.
90. Ellis, S. G., Roubin, G. S., Wilentz, J., Douglas, J. S. and King, S. B. (1989). Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am. Heart J., 117, 777-782.
91. Brack, M. J., Ray, S., Chauhan, A., Fox, J., Hubner, P. J. B., Schofield, P., Harley, A. and Gershlick, A. H. (1995). The subcutaneous heparin and angioplasty restenosis prevention (SHARP) trial. Return of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome. J. Am. Coll. Cardio., 26 (4). 947-954.
92. Lehmann, K. G., Doria, R. J., Feuer, J. M., Hall, P. X. and Hoang, D. T. (1991). Paradoxical increase in restenosis rate with chronic heparin use: final results of a randomized trial. J. Am. Coll. Cardiol., 17, 181 A.
93. Boneau, B., Dol, F., Caranobe, C., Sie, P. and Houin, G. (1989). Pharmacokinetics of heparin and related polysaccharides. Ann. N. Y. Acad. Sci., 556, 282-291.
94. Edelman, E. and Karnovsky, M. J. (1994). Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis. Circ., 89, 770-776.
95. Hajjar, D. P. (1991). Viral pathogenesis of atherosclerosis. Am. J. Path., 139, 1195-1211.
96. Koyama, H. and Reidy, M. A. (1997). Reinjury of arterial lesions induces intimal smooth muscle cell replication that is not controlled by fibroblast growth factor 2. Circ. Res., 80, 408-417.